157 related articles for article (PubMed ID: 5377613)
1. Sequential chemotherapy with cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in mice with advanced leukemia L1210.
Hoffman GS; Kline I; Gang M; Tyrer DD; Goldin A; Mantel N; Venditti JM
Cancer Chemother Rep; 1969 Oct; 53(5):265-71. PubMed ID: 5377613
[No Abstract] [Full Text] [Related]
2. Effect of different doses of methotrexate (NSC-740), cytosine arabinoside (NSC-63878), and cyclophosphamide (NSC-26271) on drug resistance in mice with L1210 leukemia.
Schmid FA; Hutchison DJ
Cancer Chemother Rep; 1972 Aug; 56(4):473-81. PubMed ID: 5081590
[No Abstract] [Full Text] [Related]
3. Chronochemotherapy of L1210 leukemic mice with cytosine arabinoside or cyclophosphamide.
Rose WC; Trader MW; Laster WR; Schabel FM
Cancer Treat Rep; 1978 Sep; 62(9):1337-49. PubMed ID: 688277
[No Abstract] [Full Text] [Related]
4. A computer model for tumor growth and chemotherapy, and its application to L1210 leukemia treated with cytosine arabinoside (NSC-63878).
Shackney SE
Cancer Chemother Rep; 1970 Dec; 54(6):399-429. PubMed ID: 5527022
[No Abstract] [Full Text] [Related]
5. Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Kline I; Woodman RJ; Gang M; Cysyk RL; Venditti JM
Cancer Chemother Rep; 1973; 57(3):291-8. PubMed ID: 4751255
[No Abstract] [Full Text] [Related]
6. Influence of route of administration on antileukemic activity of cytosine arabinoside (NSC-63878) in advanced leukemia L1210 in mice.
Kline I; Tyrer DD; Gang M; Venditti JM; Goldin A
Cancer Chemother Rep; 1968 Apr; 52(3):399-404. PubMed ID: 5670722
[No Abstract] [Full Text] [Related]
7. Studies of the L1210 antileukemic activity of O-2,2'-cyclocytidine, monoacetate (anhydro-ara-C; NSC-129220)--comparison with cytosine arabinoside (NSC-63878) with respect to treatment schedule dependency.
Venditti JM; Baratta MC; Greenberg NH; Abbott BJ; Kline I
Cancer Chemother Rep; 1972 Aug; 56(4):483-92. PubMed ID: 5081591
[No Abstract] [Full Text] [Related]
8. Influence of mitotic cycle inhibitors on the antileukemic activity of cytosine arabinoside (NSC-63878) in mice bearing leukemia L1210.
Vadlamudi S; Goldin A
Cancer Chemother Rep; 1971 Dec; 55(5):547-55. PubMed ID: 5159846
[No Abstract] [Full Text] [Related]
9. Influence of the stage of advancement of leukemia L1210 in mice on the optimal schedule of treatment of cytosine arabinoside (NSC-63878).
Kline I; Woodman RJ; Gang M; Sirica A; Venditti JM; Goldin A
Cancer Chemother Rep; 1972 Jun; 56(3):327-34. PubMed ID: 19051491
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults.
Whitecar JP; Bodey GP; Freireich EJ; McCredie KB; Hart JS
Cancer Chemother Rep; 1972 Aug; 56(4):543-50. PubMed ID: 5081596
[No Abstract] [Full Text] [Related]
11. Chronochemotherapy: L 1210 leukemia and beyond.
Halberg F; Nelson W; Cornélissen G; Haus E; Scheving LE; Good RA
Chronobiologia; 1979; 6(3):203-11. PubMed ID: 520097
[TBL] [Abstract][Full Text] [Related]
12. Selective chemotherapy for advanced murine L 1210 leukemia by combination of 2' deoxycytidine and lethal doses of cytosine-arabinoside.
Buchman VM; Svet-Maoldavsky GJ; Lichinitser MR; Mkheidze DM
Biomedicine; 1977 Jul; 27(5):179-80. PubMed ID: 922116
[TBL] [Abstract][Full Text] [Related]
13. [Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside].
Bukhman VM; Lichinitser MR; Svet-Moldavskiĭ GIa; Mkheidze DM
Biull Eksp Biol Med; 1978 Mar; 85(3):340-3. PubMed ID: 276385
[TBL] [Abstract][Full Text] [Related]
14. Cytosine arabinoside (NSC-63878)--clinical brochure.
Livingston RB; Carter SK
Cancer Chemother Rep 3; 1968 Dec; 1(1):179-205. PubMed ID: 4989814
[No Abstract] [Full Text] [Related]
15. Effect of combined therapy with cytosine arabinoside (NSC-63878) and l,3-bis-(2-chloroethyl)-1-nitrosourea (NSC-409962) on sarcoma 180 and L1210 in vivo.
Mizuno NS; Humphrey EW
Cancer Chemother Rep; 1969 Sep; 53(4):215-21. PubMed ID: 5384462
[No Abstract] [Full Text] [Related]
16. Enhancement of the cancer chemotherapeutic effect of cytosine arabinoside entrapped in liposomes on mouse leukemia L-1210.
Kobayashi T; Tsukagoshi S; Sakurai Y
Gan; 1975 Dec; 66(6):719-20. PubMed ID: 1225724
[No Abstract] [Full Text] [Related]
17. Single versus combination chemotherapy of L1210 leukemia.
Koza I; Balázová E; Ujházy V
Neoplasma; 1980; 27(6):691-6. PubMed ID: 7254424
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy with cytosine arabinoside, L-asparaginase, and 6-azauridine for transplantable murine leukemias.
Avery TL; Roberts D
Cancer Res; 1973 Apr; 33(4):791-9. PubMed ID: 4696479
[No Abstract] [Full Text] [Related]
19. Letter: Proposed new derivative of cytosine arabinoside (NSC-63878) to circumvent resistance.
Cysyk RL
Cancer Chemother Rep; 1974; 58(3):298-9. PubMed ID: 4842665
[No Abstract] [Full Text] [Related]
20. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. IX.
Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
Cancer Chemother Rep 2; 1971 Apr; 2(1):65-133. PubMed ID: 5565539
[No Abstract] [Full Text] [Related]
[Next] [New Search]
